Novo Nordisk A/S (NYSE:NVO) Shares Sold by Belpointe Asset Management LLC

Belpointe Asset Management LLC trimmed its position in Novo Nordisk A/S (NYSE:NVO) by 52.4% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 5,396 shares of the company’s stock after selling 5,938 shares during the quarter. Belpointe Asset Management LLC’s holdings in Novo Nordisk A/S were worth $464,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of NVO. Mariner LLC increased its position in shares of Novo Nordisk A/S by 4.8% during the fourth quarter. Mariner LLC now owns 363,313 shares of the company’s stock worth $31,251,000 after purchasing an additional 16,634 shares in the last quarter. Menora Mivtachim Holdings LTD. purchased a new stake in shares of Novo Nordisk A/S during the fourth quarter worth $72,512,000. Savvy Advisors Inc. raised its position in shares of Novo Nordisk A/S by 91.1% in the fourth quarter. Savvy Advisors Inc. now owns 7,123 shares of the company’s stock valued at $613,000 after buying an additional 3,395 shares during the last quarter. Synovus Financial Corp lifted its stake in shares of Novo Nordisk A/S by 26.3% in the fourth quarter. Synovus Financial Corp now owns 69,094 shares of the company’s stock worth $5,944,000 after buying an additional 14,397 shares in the last quarter. Finally, Stamos Capital Partners L.P. boosted its position in Novo Nordisk A/S by 730.8% during the fourth quarter. Stamos Capital Partners L.P. now owns 17,280 shares of the company’s stock worth $1,486,000 after acquiring an additional 15,200 shares during the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Down 2.5 %

Shares of NYSE:NVO opened at $62.88 on Thursday. The business has a 50-day moving average price of $76.55 and a 200 day moving average price of $92.55. Novo Nordisk A/S has a 12-month low of $59.32 and a 12-month high of $148.15. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $282.18 billion, a price-to-earnings ratio of 19.11, a PEG ratio of 0.90 and a beta of 0.61.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Sell-side analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently declared a semi-annual dividend, which was paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st were paid a dividend of $0.7874 per share. This represents a yield of 1.2%. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date was Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio is 49.54%.

Wall Street Analysts Forecast Growth

NVO has been the topic of a number of research reports. BMO Capital Markets decreased their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Kepler Capital Markets upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday, March 13th. Finally, Morgan Stanley started coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an “equal weight” rating for the company. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, Novo Nordisk A/S currently has an average rating of “Moderate Buy” and an average target price of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.